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Theranostic Strategy Against Plaque Angiogenesis*
Eloisa Arbustini, MD, FESC, Fabiana Isabella Gambarin, MD
Pavia, ItalyPlaque destabilization and rupture are the major
pathologic substrates of coronary thrombosis and
acute coronary syndromes (1). Contributing to these,
intraplaque hemorrhage is one of the most important
accompaniments of plaque rupture (2). Hemorrhagic
events in coronary plaques are confirmed by the
presence of morphologically recognizable red cells,
hemosiderin, or by glycophorin A immunoreactive
material. Glycophorin A is exclusively associated with
red blood cell membranes (3). In atherosclerosis
See page 624
causedbychronicthromboembolicpulmonaryhyper-
tension, thrombotic material seems to be the sole
contributor to plaque formation, and glycophorin A
immunoreactive material is the major constituent of
the pultaceous-lipid cores of the pulmonary athero-
sclerotic plaques (4). Subsequent experimental and
human studies have confirmed the role of red cell
membranes in the composition of plaque cores.
They also have documented that microhemorrhages
and angioneogenesis typically occur in plaques with
large cores (5) and play a critical role in plaque
progression and rupture (Fig. 1) (6,7). Microvessel-
related intraplaque hemorrhage is a potent stimulus
for macrophage activation and plaque inflamma-
tion, which is also associated intimately with high
risk of plaque rupture (8,9). Therefore, angioneo-
genesis is a potential therapeutic target for plaque
stabilization. Current medical therapies of ischemic
heart disease include statins that primarily reduce
circulating lipids and cholesterol but also influence
plaque stabilization through anti-inflammatory and
anti-angiogenetic effects (10).
*Editorials published in JACC: Cardiovascular Imaging reflect the views of
the authors and do not necessarily represent the views of JACC: Cardio-
vascular Imaging or the American College of Cardiology.From the Centre for Inherited Cardiovascular Diseases, IRCCS Foun-
dation Policlinico San Matteo, Pavia, Italy.Furthermore, novel agents specifically acting on
moieties expressed by neoangiogenic growth could
offer plaque stabilization; integrins are one such
target (11). Integrins are glycoproteins that com-
prise noncovalently bound alpha and beta subunits.
Numerous combinations of the alpha and beta
chains form an array of integrin heterodimers,
which can specifically interact with extracellular
matrix proteins and soluble ligands (12). Their
affinity depends on the extent of activation, and the
integrin-mediated signaling has been reported to
influence tumor cell proliferation, survival, and
apoptosis. The 3 integrin is a well-characterized
heterodimeric adhesion molecule that is widely
expressed by vascular endothelial and smooth mus-
cle cells and plays a critical role in cell migration and
cellular adhesion in addition to the formation of
new blood vessels (12,13). The 3 integrin typi-
cally is expressed by neoangiogenic sprouting and,
therefore, is considered a general marker of angio-
genesis (14). A molecular imaging approach uses
paramagnetic nanoparticles targeted to 3 inte-
grins to detect and characterize angiogenesis asso-
ciated with growth factor expression (15), tumor
growth (13), and atherosclerosis (11). From the
initial diagnostic rationale (11), targeting nanopar-
ticles have been used as carriers of therapeutic
molecules (fumagillin) introducing the “theranos-
tic” (i.e., therapeutic  diagnostic) strategy in the
setting of atherosclerosis (Fig. 1) (16).
A number of inhibitors of various integrins are
currently in clinical trials for the management of
malignancies (17). TNP-470, a soluble form of
fumagillin, is an antiangiogenetic drug that targets
the metalloprotease methionine aminopeptidase-2,
which is involved in the protein synthesis regulation
(18). Fumagillin decreases both neovascular prolif-
eration and plaque development in experimental
atherosclerosis when administered in high doses
(19). However, the doses necessary to obtain the
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636ntiatherosclerotic therapeutic effect also produce
evere adverse effects in humans (20). In their
arlier report, Winter et al. (21) combined the
elivery of fumagillin with 3 integrin-targeted
aramagnetic nanoparticles, eliciting a marked an-
iangiogenetic response with a 50,000 times lower
rug dose.
In this issue of iJACC (JACC: Cardiovascular
maging), Winter et al. (22) go a step forward and
ttempt quantification of the efficacy of theranos-
ic drug administration. This strategy allows the
imultaneous detection and monitoring of the
herapeutic target and efficient treatment. The
rst aim of the study was to assess whether
 3 -driven fumagillin could be effective when
dministered at very low doses. The second aim
as to test whether the effects of acute adminis-
ration of fumagillin was maintained over time
hen combined with daily statin treatment.
They observed that  3 -targeted fumagillin
anoparticles reduced aortic neovascular signal by
 week and maintained the efficacy over the next
Role of Neoangiogenesis in Plaque Vulnerability
agniﬁcation view of a coronary atherosclerotic plaque with promi-
vasorum containing red cells that are immunostained with anti-
n A antibodies. (B) A parafﬁn section of a large coronary
otic plaque immunostained with anti-CD34 antibodies is shown.
network of newly formed vessels is embedded in an intense
ry background that surrounds the core of the plaque. (C) Pulta-
showing both intact and fragmented red cells immunostained
lycophorin A antibodies. (D) Hemorrhage of a small coronary
ggesting that intraplaque bleeding is a common phenomenon. weeks. They also compared the antiangioge- 2etic effect of atorvastatin alone and in combina-
ion with   3 -targeted fumagillin nanoparticles.
he combination lowered the neovascularization
agnetic resonance signal and maintained it up
o 8 weeks. They further demonstrated that the
ombined administration of fumagillin with
tatins was safe; liver enzymes levels showed mild
ncreases but did not exceed upper normal values,
hich was similar to statin administration alone.
here was no difference in other biochemical
rofile between the statin treatment and the
ombined-treatment groups; only platelet count
xceeded the upper normal level in the combined
reatment group. Further investigation is needed
o assess the potential risk of thrombosis due to
hrombocytosis associated with the fumagillin
reatment.
This study provides new indications relevant for
he future theranostic strategies in the field of
laque stabilization targeted against local angioneo-
enesis. The burden of atherosclerotic disease in the
estern society is a strong incentive for research and
evelopment of new therapeutic strategies that can
ither act in very early stages of the disease or
revent complications. Clinical trials based on
anomedical approaches are ongoing in malignancy
o combat metastasis dissemination; most of them
re aimed at investigating the efficacy of paclitaxel
lbumin-stabilized nanoparticle formulation in
etastatic solid tumors or breast cancer (23). Win-
er et al. (22) propose a theranostic strategy in the
eld of atherosclerotic plaques with angioneogen-
sis to prevent or combat plaque hemorrhage and
estabilization. Further research would test how the
ffects of the combined therapy endure beyond the
rst 8 weeks. Nonetheless, the novel strategy of
electively driving therapeutic molecules on specific
argets opens new field of research for preventing
laque destabilization. The clinical need, the bio-
ogically plausible hypothesis, and the proven fea-
ibility in the experimental setting make this new
pproach an attractive area of development of new
reatments for plaque stabilization in vivo.
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